112 related articles for article (PubMed ID: 35906336)
1. Who are the long-term survivors of recurrent ovarian carcinoma?: a retrospective analysis of a multicenter study.
Yoshihara M; Mogi K; Kitami K; Uno K; Iyoshi S; Tano S; Fujimoto H; Miyamoto E; Yoshikawa N; Emoto R; Matsui S; Kajiyama H
Int J Clin Oncol; 2022 Oct; 27(10):1660-1668. PubMed ID: 35906336
[TBL] [Abstract][Full Text] [Related]
2. What Characterizes Long-term Survivors of Recurrent Ovarian Cancer? Case Report and Review of the Literature.
Hilal Z; Schultheis B; Hartmann F; Dogan A; Cetin C; Krentel H; Schiermeier S; Tempfer CB
Anticancer Res; 2016 Oct; 36(10):5365-5371. PubMed ID: 27798900
[TBL] [Abstract][Full Text] [Related]
3. Who are the long-term survivors of high grade serous ovarian cancer?
Hoppenot C; Eckert MA; Tienda SM; Lengyel E
Gynecol Oncol; 2018 Jan; 148(1):204-212. PubMed ID: 29128106
[TBL] [Abstract][Full Text] [Related]
4. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.
Zang RY; Zhang ZY; Li ZT; Chen J; Tang MQ; Liu Q; Cai SM
J Surg Oncol; 2000 Sep; 75(1):24-30. PubMed ID: 11025458
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of outcomes of secondary debulking surgery for recurrent epithelial ovarian cancer with favorable prognostic factors.
Nasu K; Kai K; Hirakawa T; Nishida M; Matsumoto H; Kawano Y; Narahara H
J Obstet Gynaecol Res; 2014 Mar; 40(3):791-6. PubMed ID: 24245582
[TBL] [Abstract][Full Text] [Related]
6. Clinical features of long-term survivors of recurrent epithelial ovarian cancer.
Iwase H; Takada T; Iitsuka C; Nomura H; Abe A; Taniguchi T; Sakamoto K; Takizawa K; Takeshima N
Int J Clin Oncol; 2015 Feb; 20(1):143-9. PubMed ID: 24664306
[TBL] [Abstract][Full Text] [Related]
7. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study.
Ferrero A; Ditto A; Giorda G; Gadducci A; Greggi S; Daniele A; Fuso L; Panuccio E; Scaffa C; Raspagliesi F; Sismondi P; Biglia N
Eur J Surg Oncol; 2014 Jul; 40(7):891-8. PubMed ID: 24378007
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and prognostic inflection points among long-term survivors of advanced epithelial ovarian cancer.
Son JH; Kong TW; Paek J; Song KH; Chang SJ; Ryu HS
Int J Gynaecol Obstet; 2017 Dec; 139(3):352-357. PubMed ID: 28857180
[TBL] [Abstract][Full Text] [Related]
9. Long-term post-recurrence survival outcomes in young women receiving fertility-sparing surgery for epithelial ovarian cancer.
Shigeyama M; Yoshihara M; Kitami K; Mogi K; Uno K; Iyoshi S; Tano S; Yoshikawa N; Kajiyama H
Eur J Obstet Gynecol Reprod Biol; 2021 Dec; 267():221-225. PubMed ID: 34826670
[TBL] [Abstract][Full Text] [Related]
10. Ascites volume at the time of primary debulking and overall survival of patients with advanced epithelial ovarian cancer.
Nasioudis D; Byrne M; Ko EM; Haggerty AF; Cory L; Giuntoli Ii RL; Kim SH; Latif NA
Int J Gynecol Cancer; 2021 Dec; 31(12):1579-1583. PubMed ID: 34702746
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Survival After Surgery and Radiotherapy for Recurrent or Persistent Ovarian and Tubal Cancer.
Rome R; Dipnall J; Leung S
Int J Gynecol Cancer; 2018 Jul; 28(6):1090-1100. PubMed ID: 29846300
[TBL] [Abstract][Full Text] [Related]
12. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
[TBL] [Abstract][Full Text] [Related]
13. Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study.
Lopes A; Rangel Costa RL; di Paula R; Anton C; Calheiros Y; Sartorelli V; Kanashiro YM; de Lima JA; Yamada A; Pinto GLS; Vianna MR; Nogueira Dias Genta ML; Ribeiro U; Dos Santos MO
Int J Gynecol Cancer; 2019 Jan; 29(1):188-194. PubMed ID: 30640703
[TBL] [Abstract][Full Text] [Related]
14. [How to increase the optimal rate of secondary cytoreductive surgery in recurrent epithelial ovarian cancer].
Li YF; Li MD; Liu FY; Liu JH; Li JD
Ai Zheng; 2003 Nov; 22(11):1193-6. PubMed ID: 14613651
[TBL] [Abstract][Full Text] [Related]
15. A large-scale multi-institutional study evaluating prognostic aspects of positive ascites cytology and effects of therapeutic interventions in epithelial ovarian cancer.
Yoshihara M; Emoto R; Kitami K; Iyoshi S; Uno K; Mogi K; Tano S; Yoshikawa N; Matsui S; Kajiyama H
Sci Rep; 2021 Jul; 11(1):15154. PubMed ID: 34312408
[TBL] [Abstract][Full Text] [Related]
16. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
Salani R; Santillan A; Zahurak ML; Giuntoli RL; Gardner GJ; Armstrong DK; Bristow RE
Cancer; 2007 Feb; 109(4):685-91. PubMed ID: 17219441
[TBL] [Abstract][Full Text] [Related]
17. Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis.
Baum J; Braicu EI; Hunsicker O; Vergote I; Concin N; Van Nieuwenhuysen E; Feldheiser A; Achimas-Cadariu P; Darb-Esfahani S; Berger A; Fetica B; Mahner S; Papadia A; Wölber L; Gasparri ML; Vanderstichele A; Benedetti Panici P; Mueller MD; Ruscito I; Woopen H; Sehouli J
Int J Gynecol Cancer; 2021 May; 31(5):713-720. PubMed ID: 33563640
[TBL] [Abstract][Full Text] [Related]
18. The role of F18-FDG PET/CT in predicting secondary optimal de-bulking in patients with recurrent ovarian cancer.
Amit A; Hodes A; Lavie O; Keidar Z; Matanes E; Lowenstein L
Surg Oncol; 2017 Dec; 26(4):347-351. PubMed ID: 29113651
[TBL] [Abstract][Full Text] [Related]
19. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
[TBL] [Abstract][Full Text] [Related]
20. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.
Previs RA; Bevis KS; Huh W; Tillmanns T; Perry L; Moore K; Chapman J; McClung C; Kiet T; Java J; Chan J; Secord AA
Gynecol Oncol; 2014 Mar; 132(3):531-6. PubMed ID: 24472410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
